Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2059-2066

  Lemaire, Sandrine ^a,b   Mingeot Leclercq, Marie Paule ^a   Tulkens, Paul M ^a   Van Bambeke, Françoise ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; ORITAVANCIN; REACTIVE OXYGEN METABOLITE; VANCOMYCIN;

ANIMAL CELL; ARTICLE; BACTERIAL COUNT; CELL METABOLISM; CELL PH; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACCUMULATION; HUMAN; HUMAN CELL; LUNG ALVEOLUS MACROPHAGE; LYSOSOME; MACROPHAGE; MACROPHAGE FUNCTION; MAXIMUM PLASMA CONCENTRATION; MITOCHONDRION; MONOCYTE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PINOCYTOSIS; PRIORITY JOURNAL; PROTEIN BINDING; PSEUDOMONAS AERUGINOSA; THP 1 CELL;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; GLYCOPEPTIDES; HUMANS; MACROPHAGES; MICE; PHAGOCYTOSIS; REACTIVE OXYGEN SPECIES;

EID: 84897007564     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02475-13     Document Type: Article

References (57)

1. Schooley R, Wilson C. 2010. Host responses to infection, p 30-44. In Cohen J, Powderly WG, Opal SM (ed), Infectious diseases. Elsevier, Dordrecht, The Netherlands.
2. Van Bambeke F, Barcia-Macay M, Lemaire S, Tulkens PM. 2006. Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr. Opin. Drug Discov. Devel. 9:218-230.
3. Tyteca D, Van Der SP, Mettlen M, Van Bambeke F, Tulkens PM, Mingeot-Leclercq MP, Courtoy PJ. 2002. Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptormediated endocytosis, but does not impair phagocytosis in J774 macrophages. Exp. Cell Res. 281:86-100. http://dx.doi.org/10.1006/excr.2002.5613. (Pubitemid 35373785)
4. Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, Grimsey NJ, Cusens D, Coulter S, Cooper J, Bowden AR, Newton SM, Kampmann B, Helm J, Jones A, Haworth CS, Basaraba RJ, DeGroote MA, Ordway DJ, Rubinsztein DC, Floto RA. 2011. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J. Clin. Invest. 121:3554-3563. http://dx.doi.org/ 10.1172/JCI46095.
5. Murphy BS, Sundareshan V, Cory TJ, Hayes D, Jr, Anstead MI, Feola DJ. 2008. Azithromycin alters macrophage phenotype. J. Antimicrob. Chemother. 61:554-560. http://dx.doi.org/10.1093/jac/dkn007. (Pubitemid 351321127)
6. Fischer S, Adam D. 2001. Effects of moxifloxacin on neutrophil phagocytosis, burst production, and killing as determined by a whole-blood cytofluorometric method. Antimicrob. Agents Chemother. 45: 2668-2669. http://dx.doi.org/10.1128/AAC.45.9.2668-2669.2001. (Pubitemid 32801932)
7. Hall IH, Schwab UE, Ward ES, Ives TJ. 2003. Effects of moxifloxacin in zymogen A or S. aureus stimulated human THP-1 monocytes on the inflammatory process and the spread of infection. Life Sci. 73:2675-2685. http://dx.doi.org/10.1016/S0024-3205(03)00611-8. (Pubitemid 37123119)
8. Dalhoff A, Shalit I. 2003. Immunomodulatory effects of quinolones. Lancet Infect. Dis. 3: 359-371. http://dx.doi.org/10.1016/S1473-3099(03)00658-3. (Pubitemid 36718015)
9. Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. 2004. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 64:913-936. http://dx.doi.org/10.2165/00003495-200464090-00001. (Pubitemid 38608472)
10. Billstein S, Eagle J. 2011. Overview of oritavancin. Eur. Infect. Dis. 11:98-101.
11. Rodvold KA. 2004. Plasma and intrapulmonary concentrations of oritavancin and vancomycin in normal healthy adults, O254. 14th Eur. Congr. Clin. Microbiol. Infect. Dis., Prague, Czech Republic.
12. Van Bambeke F, Carryn S, Seral C, Chanteux H, Tyteca D, Mingeot-Leclercq MP, Tulkens PM. 2004. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob. Agents Chemother. 48:2853-2860. http://dx.doi.org/10. 1128/AAC.48.8.2853-2860.2004.
13. Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. 2006. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob. Agents Chemother. 50:841-851. http://dx.doi.org/10.1128/AAC.50.3.841-851.2006. (Pubitemid 43327786)
14. Lemaire S, Kosowska-Shick K, Julian K, Tulkens PM, Van Bambeke F, Appelbaum PC. 2008. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis. Clin. Microbiol. Infect. 14:766-777. http://dx.doi.org/10.1111/j.1469-0691.2008.02035.x.
15. Van Bambeke F, Saffran J, Mingeot-Leclercq MP, Tulkens PM. 2005. Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation. Antimicrob. Agents Chemother. 49:1695-1700. http://dx.doi.org/10. 1128/AAC.49.5.1695-1700.2005. (Pubitemid 40631576)
16. Baquir B, Lemaire S, Van Bambeke F, Tulkens PM, Lin L, Spellberg B. 2012. Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin. Clin. Infect. Dis. 54(Suppl 3):S229-S232. http://dx.doi.org/10. 1093/cid/cir921.
17. Schwende H, Fitzke E, Ambs P, Dieter P. 1996. Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25- dihydroxyvitamin D3. J. Leukoc. Biol. 59:555-561. (Pubitemid 26156616)
18. Faull RJ, Kovach NL, Harlan JM, Ginsberg MH. 1994. Stimulation of integrin-mediated adhesion of T lymphocytes and monocytes: two mechanisms with divergent biological consequences. J. Exp. Med. 179:1307-1316. http://dx.doi.org/10.1084/jem.179.4.1307. (Pubitemid 24091789)
19. Snyderman R, Pike MC, Fischer DG, Koren HS. 1977. Biologic and biochemical activities of continuous macrophage cell lines P388D1 and J774.1. J. Immunol. 119:2060-2066. (Pubitemid 8232105)
20. Carlier MB, Garcia-Luque I, Montenez JP, Tulkens PM, Piret J. 1994. Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture. Int. J. Tissue React. 16:211-220.
21. Van Bambeke F, Montenez JP, Piret J, Tulkens PM, Courtoy PJ, Mingeot-Leclercq MP. 1996. Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. Eur. J. Pharmacol. 314:203-214. (Pubitemid 26378905)
22. Arhin FF, Sarmiento I, Belley A, McKay GA, Draghi DC, Grover P, Sahm DF, Parr TR, Jr, Moeck G. 2008. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob. Agents Chemother. 52:1597-1603. http://dx.doi.org/10.1128/AAC.01513-07. (Pubitemid 351614648)
23. Carryn S, Van de Veide S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. 2004. Impairment of growth of Listeria monocytogenes in THP-1 macrophages by granulocyte macrophage colony-stimulating factor: release of tumor necrosis factor-alpha and nitric oxide. J. Infect. Dis. 189:2101-2109. http://dx.doi.org/10.1086/420848. (Pubitemid 38692292)
24. Theus SA, Cave MD, Eisenach KD. 2004. Activated THP-1 cells: an attractive model for the assessment of intracellular growth rates of Mycobacterium tuberculosis isolates. Infect. Immun. 72:1169-1173. http://dx.doi.org/10.1128/IAI.72.2.1169-1173.2004. (Pubitemid 38166704)
25. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
26. Ouadrhiri Y, Scorneaux B, Sibille Y, Tulkens PM. 1999. Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by gamma interferon. Antimicrob. Agents Chemother. 43:1242-1251. (Pubitemid 29214754)
27. Renard C, Vanderhaeghe HJ, Claes PJ, Zenebergh A, Tulkens PM. 1987. Influence of conversion of penicillin G into a basic derivative on its accumulation and subcellular localization in cultured macrophages. Antimicrob. Agents Chemother. 31:410-416. http://dx.doi.org/10.1128/AAC.31.3.410. (Pubitemid 17027130)
28. Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH. 2010. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One 5:e8668. http://dx.doi.org/10. 1371/journal.pone.0008668.
29. Shiratsuchi A, Watanabe I, Ju JS, Lee BL, Nakanishi Y. 2008. Bridging effect of recombinant human mannose-binding lectin in macrophage phagocytosis of Escherichia coli. Immunology 124:575-583. http://dx.doi.org/10.1111/j.1365- 2567.2008.02811.x. (Pubitemid 351962553)
30. Descamps D, Le Gars M, Balloy V, Barbier D, Maschalidi S, Tohme M, Chignard M, Ramphal R, Manoury B, Sallenave JM. 2012. Toll-like receptor 5 (TLR5), IL-1beta secretion, and asparagine endopeptidase are critical factors for alveolar macrophage phagocytosis and bacterial killing. Proc. Natl. Acad. Sci. U. S. A. 109:1619-1624. http://dx.doi.org/10.1073/pnas.1108464109.
31. Agramonte-Hevia J, Gonzalez-Arenas A, Barrera D, Velasco-Velazquez M. 2002. Gram-negative bacteria and phagocytic cell interaction mediated by complement receptor 3. FEMS Immunol. Med. Microbiol. 34:255-266. http://dx.doi.org/10.1016/S0928-8244(02)00408-X. (Pubitemid 35351375)
32. Buyck JM, Tulkens PM, Van Bambeke F. 2013. Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes. Antimicrob. Agents Chemother. 57: 2310-2318. http://dx.doi.org/10.1128/AAC.02609-12.
33. Wang E, Michl J, Pfeffer LM, Silverstein SC, Tamm I. 1984. Interferon suppresses pinocytosis but stimulates phagocytosis in mouse peritoneal macrophages: related changes in cytoskeletal organization. J. Cell Biol. 98:1328-1341. http://dx.doi.org/10.1083/jcb.98.4.1328. (Pubitemid 14128917)
34. Fautz R, Husein B, Hechenberger C. 1991. Application of the neutral red assay (NR assay) to monolayer cultures of primary hepatocytes: rapid colorimetric viability determination for the unscheduled DNA synthesis test (UDS). Mutat. Res. 253:173-179. http://dx.doi.org/10.1016/0165-1161(91)90130-Z.
35. Fotakis G, Timbrell JA. 2006. In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol. Lett. 160:171-177. http://dx.doi.org/10. 1016/j.toxlet.2005.07.001. (Pubitemid 41578961)
36. Repetto G, del Peso A, Zurita JL. 2008. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat. Protoc. 3:1125-1131. http://dx.doi.org/10.1038/nprot.2008.75.
37. Bulychev A, Trouet A, Tulkens P. 1978. Uptake and intracellular distribution of neutral red in cultured fibroblasts. Exp. Cell Res. 115:343-355. http://dx.doi.org/10.1016/0014-4827(78)90288-4. (Pubitemid 9040392)
38. de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. 1974. Commentary. Lysosomotropic agents. Biochem. Pharmacol. 23:2495-2531. http://dx.doi.org/10.1016/0006-2952(74)90174-9.
39. Nelson N, Harvey WR. 1999. Vacuolar and plasma membrane protonadenosinetriphosphatases. Physiol. Rev. 79:361-385.
40. Berridge MV, Herst PM, Tan AS. 2005. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol. Annu. Rev. 11:127-152. http://dx.doi.org/10.1016/S1387-2656(05)11004-7. (Pubitemid 41510276)
41. Berridge MV, Tan AS. 1993. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch. Biochem. Biophys. 303:474-482. http://dx.doi.org/10.1006/abbi.1993.1311. (Pubitemid 23199849)
42. Nathan C, Shiloh MU. 2000. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc. Natl. Acad. Sci. U. S. A. 97:8841-8848. http://dx.doi.org/10.1073/pnas.97.16.8841. (Pubitemid 30626635)
43. Belley A, Arhin FF, Sarmiento I, Deng H, Rose W, Moeck G. 2013. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection. Antimicrob. Agents Chemother. 57:205-211. http://dx.doi.org/10.1128/AAC.01428-12.
44. Albrecht LM, Rybak MJ, Warbasse LH, Edwards DJ. 1991. Vancomycin protein binding in patients with infections caused by Staphylococcus aureus. DICP 25:713-715.
45. Berthoin K, Ampe E, Tulkens PM, Carryn S. 2009. Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections. Int. J. Antimicrob. Agents 34:555-560. http://dx.doi.org/10.1016/j. ijantimicag.2009.08.005.
46. Rodvold KA, Danziger LH, Gotfried MH. 2003. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob. Agents Chemother. 47:2450-2457. http://dx.doi.org/ 10.1128/AAC.47.8.2450-2457.2003. (Pubitemid 36919444)
47. Foulds G, Shepard RM, Johnson RB. 1990. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25(Suppl A):73-82. (Pubitemid 20043952)
48. Carryn S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. 2002. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob. Agents Chemother. 46:2095-2103. http://dx.doi.org/10.1128/AAC.46.7.2095-2103.2002. (Pubitemid 34665902)
49. Underhill DM, Ozinsky A. 2002. Phagocytosis of microbes: complexity in action. Annu. Rev. Immunol. 20:825-852. http://dx.doi.org/10.1146/annurev. immunol.20.103001.114744. (Pubitemid 34293441)
50. Li Q, Jagannath C, Rao PK, Singh CR, Lostumbo G. 2010. Analysis of phagosomal proteomes: from latex-bead to bacterial phagosomes. Proteomics 10:4098-4116. http://dx.doi.org/10.1002/pmic.201000210.
51. Xu JJ, Diaz D, O'Brien PJ. 2004. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem. Biol. Interact. 150:115-128. http://dx.doi.org/10.1016/j.cbi.2004.09.011. (Pubitemid 39441298)
52. Weyermann J, Lochmann D, Zimmer A. 2005. A practical note on the use of cytotoxicity assays. Int. J. Pharm. 288:369-376. http://dx.doi.org/10.1016/j. ijpharm.2004.09.018. (Pubitemid 40038590)
53. Ohkuma S, Poole B. 1978. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc. Natl. Acad. Sci. U. S. A. 75:3327-3331. http://dx.doi.org/10.1073/pnas.75. 7.3327. (Pubitemid 8389720)
54. Denamur S, Tyteca D, Marchand-Brynaert J, Van Bambeke F, Tulkens PM, Courtoy PJ, Mingeot-Leclercq MP. 2011. Role of oxidative stress in lysosomal membrane permeabilization and apoptosis induced by gentamicin, an aminoglycoside antibiotic. Free Radic. Biol. Med. 51:1656-1665. http://dx.doi.org/10.1016/j. freeradbiomed.2011.07.015.
55. Servais H, Van Der Smissen P, Thirion G, Van der Essen G, Van Bambeke F, Tulkens PM, Mingeot-Leclercq MP. 2005. Gentamicininduced apoptosis in LLC-PK1 cells: involvement of lysosomes and mitochondria. Toxicol. Appl. Pharmacol. 206:321-333. http://dx.doi.org/10.1016/j.taap.2004.11.024. (Pubitemid 41020674)
56. Garcia LG, Lemaire S, Kahl BC, Becker K, Proctor RA, Tulkens PM, Van Bambeke F. 2012. Influence of the protein kinase C activator, phorbol myristate acetate (PMA), on the intracellular activity of antibiotics against hemin and menadione auxotrophic small-colony variant (SCV) mutants of Staphylococcus aureus and their wild-type parental strain in human THP-1 cells. Antimicrob. Agents Chemother. 56:6166-6174. http://dx.doi.org/10.1128/AAC.01031-12.
57. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. 2007. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130:797-810. http://dx.doi.org/10.1016/j.cell.2007.06.049. (Pubitemid 47332566)